Phase 3 trial in metastatic NSCLC with disease control after 6 months of nivolumab-ipilimumab (71 randomised; stopped early): stopping vs continuing gave per-protocol median PFS not reached vs 18.7 months, with fewer grade 3-5 treatment-related adverse events (23.5% vs 54.3%).
RCTn = 71 patients
Zalcman et al. Four-Year Outcomes of First-Line Nivolumab Plus Ipilimumab for 6 Months Versus Continuation in Patients With Advanced NSCLC: Results of the Randomized IFCT-1701 "DICIPLE" Phase III Trial